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ABSTRACT
AMINOGLYCOSIDE-ASSOCIATED

DIZZINESS

IN

GERIATRIC

PATIENTS: A PROSPECTIVE OBSERVATIONAL COHORT STUDY.
Richard G. Ihnat and Mary E. Tinetti.

Department of Internal Medicine,

Yale University, School of Medicine, New Haven, CT.

To determine if the elderly have an increased risk of aminoglycosideinduced vestibular damage, 42 subjects over the age of 65 who had received at
least five consecutive days of either an aminoglycoside (exposed subjects) or
one of a list of control antibiotics (unexposed subjects) were questioned as to
the presence of dizziness symptoms after their discharge from the hospital.
Laboratory and diagnostic data were also abstracted from their medical
records.
Two exposed subjects (13%) and 2 unexposed subjects (8%) reported a
new-onset of dizziness since their hospitalization (p=0.63). Dizziness increased
in severity for 3 (19%) exposed and 2 (8%) unexposed subjects (p=0.36). An
overall worsening of dizziness was noted in 3 (19%) exposed and 3 (12%)
unexposed subjects (p=0.66). Although these differences were not statistically
significant due to the low power of the study, they indicate a trend may be
present. We conclude that an increased risk of dizziness symptoms secondary
to aminoglycoside administration has not been proven but may be present and
warrants continuation of this study.
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INTRODUCTION
The aminoglycoside antibiotics have long been known to have significant
side-effects which include nephrotoxicity and vestibular and auditory toxicity.
Despite their long tenure in our clinical armamentarium, the exact mechanism
of their bactericidal and toxic side-effects remains elusive. The elderly are a
unique population which may have an increased susceptibility to the toxic sideeffects. This pilot study will specifically address the latter issue.
An understanding of the vestibular system is crucial to understanding
aminoglycoside toxicity.

A review of this system will be followed by

discussions of aminoglycoside usage, bacterial toxicity, human toxicities, and
how they relate to the elderly.

THE VESTIBULAR SYSTEM
In humans, the vestibular system is responsible for maintaining balance,
coordinating eye, head, and body movements, and enabling the eye to fixate
on a point while the head is moving. The membranous labyrinth of the middle
ear’s vestibular apparatus is composed of three semicircular canals, which are
oriented in planes 90 degrees apart, and the saccule and the utricle.

These

structures are housed in the bony labyrinth of the petrous bone and are
separated from it by a fluid called perilymph. The semicircular canals supply
information about angular acceleration of the head while the utricle provides
information about linear acceleration and head position with respect to gravity.
The function of the saccule is unknown but is felt to be similar to that of the
utricle. The lumens of these structures are connected with each other as well
as with the cochlea, and they are filled with a common pool of fluid called
endolymph (Kandel & Schwartz, 1985).
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The vestibular hair cells are the key sensory cells, and they are located
in the ampullae of the semicircular canals and the macula of the utricle. On
its luminal membrane, each hair cell has one kinocilium and several stereocilia
which project into the endolymph. These projections are oriented along the
cell membrane so that the kinocilium is lateral to the stereocilia.

When the

head accelerates, the viscous endolymph lags behind which causes it to move
relative to the hair cells of the semicircular canals. When the force of the fluid
bends the stereocilia towards the kinocilium, the cell depolarizes. When they
bend away from the kinocilium, the hair cell hyperpolarizes. In this manner,
variations from the hair cell’s baseline rate of 15 impulses per second code for
the direction of the movement. The number of cells recruited delineates the
magnitude of the acceleration (Kandel & Schwartz, 1985).
The utricle works in a manner analogous to the semicircular canals, but
motion of tiny crystals called otolith, which are embedded in a gelatinous
matrix, is substituted for the motion of the endolymph.

The otolith are

composed of calcium carbonate and rest on the hair cell cilia. With the head
in anatomical position, the macula of the utricle is in the horizontal plane. As
the force of gravity acts on the otolith which rest on the stereocilia, the cilia
are bent causing them to either hyperpolarize or depolarize depending on the
head’s orientation to gravity (Kandel & Schwartz, 1985).
Impulses from the hair cells of the canals and utricle are transmitted to
bipolar cells in the vestibular ganglia of the eighth nerve where the data is
integrated to provide information about the position and motion of the head.
Much of this data is transmitted into the cerebellum, median longitudinal
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fasciculus,

reticular

formation,

and

spinal

cord

and

thus

remains

predominantly in the unconscious realm. In concert with information provided
by the other senses, vestibular input is crucial for movement and balance.
When any part of the vestibular system breaks down, dizziness, nausea,
and ataxia result. The hair cells, which are one of the key components, are
vulnerable to a wide variety of insults, among which are the toxic effects of
drugs. This study investigated the effects of the aminoglycoside antibiotics on
the vestibular system in elderly patients.
Of the several tests used to determine if the vestibular system is intact,
the thermal test and the Romberg test are the most common. In the thermal
test, either warm or cold water is dropped into the external acoustic meatus to
simulate acceleration.

This local change in temperature sets up convection

currents in the endolymph which causes the fluid to move and influence the
hair cells. In the normal individual, this results in nystagmus. If nystagmus
is depressed or eliminated, it indicates the presence of vestibular dysfunction.
The Romberg test evaluates the utricle testing the subjects ability to maintain
balance when deprived of visual cues.
These tests, however, are somewhat insensitive, and it is difficult to
quantitate the degree of vestibular dysfunction. Dizziness, being the clinical
manifestation of vestibular dysfunction, is likewise difficult to assess or
quantitate.

Thus, dizziness is largely a subjective experience which can be

reported but not satisfactorily tested.

Consequently, this study focused on

subjective reporting of dizziness as a measure of outcome.
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AMINOGLYCOSIDES
Aminoglycoside antibiotics are derived from the soil actinomycetes
Streptomyces and Micromonospora, and they were first discovered by Selman
Waksman’s group at Rutgers University in 1944 (Schatz et al., 1944). The
aminoglycosides are stable, hydrophilic, polycationic amino sugars bound in
a glycosidic linkage to a central hexose sugar. For systemic administration,
they must be administered parenterally secondary to poor oral absorption, and
their polycationic structure is the basis for their poor central nervous system
penetration.

They are distributed predominantly in the extracellular space

compartment, and they are excreted unmetabolized by the kidney with a halflife of about two hours. The antimicrobial effects of gentamicin, tobramycin,
and netilmicin are usually achieved at peak serum concentrations of 4-8
mcgs/ml, and kanamycin is effective at 15-40 mcgs/ml.
amikacin are efficacious at 20-30 mcgs/ml.

Streptomycin and

Aminoglycosides kill in a

concentration-dependent manner. The higher the concentration, the faster the
bacteria are killed (Lampe, 1986; Gilman, 1985).
Clinically, the most commonly used aminoglycosides are streptomycin,
kanamycin (Kantrex, Kebcil), neomycin (Mycifradin, Neobotic), gentamicin
(Garamycin),

tobramycin

(Nebcin),

amikacin

(Amikin),

netilmicin

(Netromycin), paromycin (Humatin), dibekacin, and sisomicin (Siseptin). As
a class, single-agent aminoglycoside therapy is primarily used against aerobic
gram-negative bacilli (Lampe, 1986; Gilman et al., 1985). The aminoglycosides
are also commonly used in combination with other antibiotics with which they
act synergistically. Such combinations typically include cell wall inhibitors.
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such as beta-lactams or vancomycin, which are believed to damage the
peptidoglycan cell wall and allow the aminoglycosides easier access to the
bacterial cytoplasm (Plotz & Davis, 1962). This is done in serious infections
such as bacteremia, peritonitis, nosocomial pneumonia, osteomyelitis, septic
arthritis, burns, pyelonephritis, and meningitis where gram-negative bacilli are
either proven or suspected (John, 1988; Lampe, 1986 & Gilman et al., 1985).
Of particular concern is Pseudomonas aeruginosa coverage.

Gentamicin,

tobramycin, and amikacin are particularly effective in this regard.

MECHANISM IN BACTERIA
There

are

significant

pharmacokinetic

differences

among

the

aminoglycosides, and they may therefore have different methods of transport
and action (Taber et al., 1987; Arrow & Taber, 1986). As a class, unlike the
penicillin and cephalosporins, they must enter the bacteria in order to be
bactericidal. The bacterial capsule (when present), outer membrane, and cell
wall do not seem to be a significant impediment to penetration (Taber et al.,
1987; Miller et al., 1986; Peterson et al., 1985; Nichols & Slack; Nakae &
Nakae, 1982). It is interesting to note, however, that the proposed mechanism
for the synergy between beta-lactams and aminoglycosides is that the betalactam damages this wall and allows the aminoglycosides easier access to the
cytoplasm (Miller et al., 1986; Plotz & Davis, 1962). Therefore, if the cell wall
is not a significant barrier, a new explanation for this synergy must be sought.
The process by which aminoglycosides cross the inner membrane has
engendered the greatest controversy. Bryan & Van Den Elzen (1976) proposed
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an overview of the process in which aminoglycoside uptake is divided into
three phases. The first phase involves ionic binding to the inner membrane in
an energy-independent manner. In gram-negative bacteria, they would bind
to lipopolysaccharides, phospholipids, and outer membrane proteins while in
gram-positive bacteria, they would bind to phospholipids and teichoic acids
(Taber et al., 1987).

In energy-dependent phase I (EDPI) the positively

charged aminoglycosides associate with membrane "transporters” and small
amounts are shuttled across the membrane traveling down the electrical
potential energy gradient to the relatively negatively charged interior of the
cell. The slow leak of aminoglycoside into the cell during EDPI may occur at
zones of growth or through faulty protein channels which may normally exist
in nature (Davis et al., 1986).
After small quantities of drug have entered the cell during EDPI and
have bound to ribosomes, energy-dependent phase II (EDPII) begins and
allows more rapid entry of large amounts of antibiotics into the cells (Bryan
& Van Den Elzen, 1976).

Once inside the cell, the aminoglycosides bind

almost irreversibly to the 30S ribosomal subunit to create a nonfunctional
complex which blocks initiation of runoff (free) ribosomes and causes
misreading of the genetic code in polysomes. Irreversible binding to ribosomes
and subsequent loss of protein synthesis is probably at least part of the
mechanism for bacterial cell death (Taber et al., 1987).
Membrane potential (Mates et al., 1983; Miller et al., 1980), active
electron transport (Arrow & Taber, 1986; Campbell et al., 1980), and
functioning ribosomes (Taber et al., 1987; Muir et al., 1984; Davis, 1982) are
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necessary for the rapid uptake of aminoglycosides during EDPII.

These

factors may be related through the functioning of the ATP synthase molecule.
Normally, this enzyme produces ATP when the proton motive force overcomes
a threshold value.

Alternatively, the enzyme can consume ATP to create a

proton motive force. After working with E. coli mutants possessing various
combinations of functional and non-functional components of the enzyme,
Humbert and Altendorf (1989) proposed that inactive enzymes would allow
proton motive force, and therefore membrane potential, to rise and reach a
threshold level required for aminoglycoside uptake without converting the
proton motive force into ATP.

On the other hand, dysfunctional enzymes

which act as proton pores lower the proton motive force, and hence the
membrane potential, below the threshold limit for aminoglycoside uptake.
This understanding can be used to construct a model of aminoglycoside
entry. After small quantities of aminoglycoside have entered the cell during
EDPI and altered protein synthesis (Davis et ah, 1986), inactive ATP synthase
would be produced.

Under conditions of active electron transport, the

membrane potential would rise.

Since the inactive ATP synthase could not

convert the membrane potential to ATP, it would rise uncontrollably.

The

elevated membrane potential would then drive aminoglycoside molecules
through other pores created by faulty RNA translation.
The human mitochondria shares some similarities with bacterial cells in
that

it

has an

electron

transport

chain

and

bacteria-like

ribosomes.

Nevertheless, it is unclear which, if any, of the steps in bacterial cell death are
common to human toxicity.
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TOXICITY
The

side

effects

of

the

aminoglycosides,

which

therapeutic/toxic ratio compared to other antibiotics,

have

a

low

are well-known.

Ototoxicity, nephrotoxicity, neuromuscular blockade, skin rash, drug fever,
gastrointestinal upset, malabsorption, blood dyscrasias, transaminitis, retinal
damage, and peripheral neuropathies have all been described (Judson, 1989;
Edson & Terrell, 1987; Lampe, 1986 & Gilman, et ah, 1985).

The clinical

practice of measuring serum peak and trough levels of the aminoglycosides is
an attempt to avoid subjecting patients to unnecessarily high doses of these
drugs in the hope of minimizing the side effects.

There are also several

significant drug interactions which must be considered. Nephrotoxicity can be
produced by concurrent

administration of methoxyflurane (Penthrane),

amphotericin B (Fungizone), vancomycin, cisplatin (Platinol), cyclosporine
(Sandimmune), indomethacin(IndocinIV),cephalothin(Keflin),cephaloridine,
and loop diuretics such as furosemide (Lasix), bumetanide (Bumex), and
ethacrynic acid.

Additionally, neuromuscular blockade has been reported

when succinylcholine (Anectine, Quelicin, Sucostrin) or tubocurarine were used
concomitantly with aminoglycosides (Lampe, 1986).

Furthermore, in the

guinea pig, Brummett (1981) demonstrated that concurrent use of loop
diuretics and aminoglycosides results in significantly enhanced ototoxicity.
Of the aminoglycoside side-effects nephrotoxicity and ototoxicity are the
most common. The term ototoxicity encompasses both auditory and vestibular
toxicity. Of these three side-effects, vestibular damage is the most difficult to
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measure and quantitate.

Perhaps for this reason, most of the work in the

scientific literature has focused on renal and auditory toxicity.

NEPHROTOXICITY
The effect of aminoglycosides on the kidney has been extensively
studied, and the incidence of nephrotoxicity is estimated to be 3-26% of all
patients (Smith et al., 1980; Appel & Neu, 1977).

Risk factors include

hypotension, hypovolemia, advanced age, obesity, recent prior aminoglycoside
therapy, duration of treatment, preexisting renal insufficiency, and elevated
serum drug levels (Appel, 1990; Corcovan et al., 1989; Edson & Terrell, 1987;
Lampe, 1986; Cabrera et al., 1982).
Aminoglycoside nephrotoxicity begins with proteinuria, enzymuria and
cylinduria.

There is a decrease in GFR which leads to elevated BUN and

serum creatinine levels and the onset of usually nonoliguric failure seven to ten
days into therapy (Appel, 1990). These effects are reversible and cumulative
(Edson & Terrell, 1987).
Houghton’s

group

(1988)

administered

subtherapeutic

doses

of

gentamicin to rats so that the serum levels were either low or unmeasurable for
a period of six months and found that their kidneys progressed from mild
chronic tubulointerstitial nephritis to progressive renal failure.

Although

aminoglycosides would never be given in this fashion, it suggests that even
assiduous attention to peak and trough levels might still result in some renal
disease.
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The rat is an excellent model of nephrotoxicity, and Silverblatt (1982)
and Appel (1990) summarized this work.

After binding to phospholipid

receptors on the brush border of the tubular cells, gentamicin is reabsorbed
from the glomerular filtrate mainly in the proximal tubule by pinocytosis and
stored in lysosomes.

Some also remains in the cytoplasm (Wedeen et al.,

1983). Lysosomal storage accounts for the relatively high concentration found
in renal cortex and may involve irreversible binding to various cellular
constituents (Oshima et al., 1989). Gentamicin is then excreted into the urine
by reverse endocytosis and enjoys a half-life of seven days.

While in the

lysosome, high concentrations of gentamicin cause the membrane to become
leaky and inhibit the degradation of complex lipids. As these lipids build up,
they form the myeloid bodies which are seen with electron microscopy.
Gentamicin also damages the mitochondria which in turn leads to a depletion
of ATP (Simmons
compartmentalization.

et

al.,

1980) and changes

in

subcellular calcium

Other cellular changes include an inhibition of the

Na/K ATPase (Lipsky & Lietman, 1980) and a decrease in apical membrane
marker enzymes levels (Inui et al., 1988). Once proximal tubule cell damage
occurs,

it

is

vasoconstrictive

"translated"
hormones

into

a

declining

or backleak

GFR

possibly

of waste across

through

the damaged

epithelium. It is difficult to discern which changes are significant and which
are merely epiphenomena.

It is also difficult to determine which effects are

common to the mechanism of hair cell death seen in ototoxicity since the
research literature on this subject is sparse.
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OTOTOXICITY
Aminoglycoside ototoxicity involves irreversible, dose-related damage to
the hair cells of the cochlea and vestibular apparatuses of the inner ear.
Auditory toxicity is conventionally taken to mean at least a 15dB decrease in
hearing acuity in the range from 250-8,000 Hz, and vestibular toxicity is a loss
of nystagmus in the thermal test. The human attack rate for auditory toxicity,
with gentamicin and tobramycin, is 10-11% (Smith et al., 1980). Brummett &
Morrison (1990), however, used the same criteria on a group of healthy
volunteers who were not receiving any medications and found that 20-33% of
the subjects met the criteria for new-onset auditory toxicity during the course
of study. They concluded that the incidence of this complication was probably
overrated.
Since most large studies have focused on auditory damage as a measure
of aminoglycoside ototoxicity, it is difficult to obtain reliable estimates for
vestibular toxicity. Estimates from some of the larger studies of the rate in the
general population range from 0.4% - 2.5% for most of the aminoglycosides
(Arcieri et al. 1970; Neu & Bendush, 1976), but with streptomycin, the estimate
is close to 20% (Wilson et al., 1984)[Table 1].

Of the aminoglycosides,

kanamycin, neomycin, and amikacin primarily affect hearing while gentamicin
and streptomycin seem to chiefly affect the vestibular system.

Tobramycin

seems to cause both types of ototoxicity equally (Edson & Terrell, 1987;
Lampe, 1986; Gilman et al., 1985).
Clinically, patients with auditory toxicity often complain of tinnitus or
a sense of "fullness" in their ears, but by that point there may already be
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TABLE 1
AMINOGLYCOSIDE TOXICITY RATES

AGENT

N

gentamicin

34

streptomycin
tobramycin

amikacin

kanamycin

AUDITORY VESTIBULAR

CITATION

N/E

10.0%

Nordstrom etal., 1973

1484

2.3%

2.5%

Jackson & Arcieri, 1971

1327

2.0%

Arcieri et al., 1970

26

1.3%
3.8%

3.8%

Lerner et al., 1977

45

0.0%

16.0%

Tjernstrom et al., 1973

40

7.5%

23.0%

Meyers, 1970 *
Waisbren, 1969

181

N/E

2.2%

138

16.0%

15.0%

Fee, 1980

36

N/E

19.0%

Wilson et al., 1984.

138

15.0%

4.6%

Fee, 1980

3506

0.3%

0.4%

Neu & Bendush, 1976

1548
27

4.6%
7.4%

0.7%

Lane et al., 1977

0.0%

Lerner et al., 1977

55

24.0%

0.0%

Black et al., 1976

81

24.0%

9.9%

Finegold et al., 1958

N/E = Not Evaluated
* = dosage not adjusted for renal insufficiency
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permanent high frequency hearing loss (Lampe, 1986). Vestibular damage is
often manifest by a moderate head ache in the early stage lasting 1-2 days.
This is followed by 1-2 weeks of nausea, vomiting, vertigo, dizziness, an
inability to perceive termination of movement ("mental past pointing"),
difficulty focusing and reading, a positive Romberg test, and nystagmus. The
chronic phase begins suddenly and is heralded by ataxia and lasts for two
months. The compensatory stage in which the patient learns to adapt using
visual cues follows gradually until the symptoms only become apparent when
the eyes are closed.

In cases where the damage is not permanent, this

recuperation may take more than a year, and recovery is less satisfactory in
older patients (Gilman et al., 1985; Neu & Bendush, 1976).

Moreover, the

onset is variable and can be quite rapid. Miyoshi(1988) examined patients with
tuberculosis or urological infections and found that some had their first
symptoms after less than five days of treatment.

Others have reported a

delayed response in which the symptoms don’t appear until several weeks after
the drugs are discontinued (Neu & Bendush, 1976).

MECHANISM IN HUMANS
The exact mechanism of vestibular hair cell injury and how it relates to
the nephrotoxic or bactericidal mechanisms discussed previously is still not
clear. Much of the work has been done on the hair cells of the organ of Corti,
but since aminoglycosides seem to damage both vestibular and auditory hair
cells, the results are probably applicable to both. Some of the renal data may
also be applicable.
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That the aminoglycosides damage hair cells is clear.

Animal studies

have demonstrated that lesions occur at both the inner hair cells of the organ
of Corti and the vestibular hair cells (Theopold, 1977; Wersall et ah, 1973;
McGee et ah, 1969; Koide et ah, 1966; Duvall & Wersall 1964). The results
of these studies also show the eighth nerve to be spared. Huizing & de Groot
(1987) reviewed the human data and determined that in the cochlea, outer hair
cells are affected first before the inner hair cells. The stria vascularis is also
injured.

Finally, the supporting structures and nerves rapidly degenerate

secondary to hair cell loss and not due to direct drug toxicity. They did not
look at the vestibular hair cells.
The highest concentrations of aminoglycosides in the body occur in the
endolymph, perilymph, and kidney - the areas where toxicity is the greatest.
Federspil, et al. (1976) examined the perilymph of guinea pigs after a
subcutaneous bolus injection of aminoglycoside and found that the drug
concentration in the perilymph rose gradually bilaterally until it was equal to
that of the serum. Beyond that point, the serum concentration began to drop
quite precipitously, but levels in the perilymph decreased very slowly. Indeed,
after 5 hours the aminoglycoside concentration in the middle ear was much
higher than in brain, heart, and liver.

From their data, they were able to

calculate the perilymph half-lives for gentamicin (12 hours), tobramycin (11
hours), and amikacin (10 hours).
This accumulation is also seen in rats, where Huy et al. (1983) detected
gentamicin in the endolymph up to 15 days after administration of the drug
was discontinued. Whereas the serum half-life of gentamicin in the rat is only

15

40 minutes, they were unable to even calculate the half-life in the endolymph.
In humans, the half-lives of the aminoglycosides in the endolymph are up to
four times greater than the serum half-lives (Neu & Bendush 1976). The exact
clinical significance of this is unclear, but this prolonged exposure may impair
the ability of the cells to maintain the proper cation concentrations in the
endolymph and thus may lead to reversible ototoxicity (Neu & Bendush 1976).
This effect can be quite rapid. Direct injection of aminoglycoside into guinea
pig endolymph produces an immediate suppression of cochlear function
(Konishi, 1979). Wilson & Ramsden (1977) obtained similar results in humans
with systemic bolus administration, and they noted the effects to be rapid and
reversible.

They suspected this rapidity ruled out interruption of protein

synthesis as a possible mechanism. Rather, they speculated that toxicity was
due to interference with energy metabolism or cation transport.

Permanent

ototoxicity due to cell death would then result from either the long-term loss
of these gradients or to direct toxic effects on hair cells by the aminoglycosides.
Early theories as to the mechanism of the toxic side-effects implicated
the ribosomes (Spoendlin, 1966) or the cell membrane (Wersall & Flock, 1964).
Many of the current theories have focused on phospatidyl inositol (PI)
metabolism. The PI cycle is an important second messenger system which is
known to be activated by gonadotropin releasing hormone and vasopressin and
is part of the alpha-one adrenergic receptor in liver tissue (Patton et al., 1989;
Zubay, 1983). Moreover, it is activated in platelet by thrombin and collagen
to promote platelet aggregation (Polascik, 1987). When these cell membrane
receptors are occupied, phospholipase C (PLC) cleaves PI into diacylglycerol
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(DG) and inositol 1,4,5 triphosphate (IP?).

1P^ liberates calcium from the

endoplasmic reticulum until it is degraded to inositol. DG, in the presence of
the calcium liberated by IP3, activates membrane-bound kinase C. Kinase C
phosphorylates various cellular proteins and thus may control cellular division.
DG is then

phosphorylated to become phosphatidic acid (PA).

After PA

combines with cytosine triphosphate and inositol, IP3 is regenerated and the
cycle may begin again (Patton, 1989).

An alternative pathway involves the

action of diacylglycerol lipase upon PA to form arachidonic acid, the precursor
to prostaglandin synthesis (Zubay, 1983).
Interest

in

PI

metabolism

as

the

molecular

site

of injury

in

aminoglycoside toxicity began when Schacht (1976) took subcellular fragments
of guinea pig cerebral cortex and found that neomycin bound to the
polyphosphoinositide component.

Polyphosphoinositides are found in the

highest concentrations in neural tissue (Hauser & Eichberg, 1973).

Schacht

speculated that by binding to it, neomycin may block polyphosphoinositide
from acting as a substrate for phosphorylation and thus interfere with
membrane function.

Lodhi and associates (1979) duplicated this work by

demonstrating that neomycin binds to an artificial monomolecular membrane
of polyphosphoinositide.
from the membrane.

In addition, they found that it displaced calcium

From this observation, they postulated that neomycin

may act by blocking calcium that is necessary for membrane function.
Furthermore, it is known that aminoglycosides competitively inhibit
renal cytoplasmic PLC, possibly due to their structural similarity to PI (Lipsky
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& Lietman, 1982).

Not only would this alter the response of the second

messenger system, but also it would increase the concentration of PI.
Renal phospholipase A (PLA), which degrades neutral lipids, is
synergistically inhibited by aminoglycosides and PI (Hostetler & Jellison, 1990).
Hostetler & Jellison (1990) proposed that the aminoglycosides bind to PI,
which is not normally a substrate of PLA, to create a new conformation which
prevents

PLA

from

interacting

with

its

usual

substrate.

Clearly,

aminoglycoside inhibition of PLC would lead to an accumulation of PI and
subsequently inhibition of PLA. This chain reaction might then cause a build¬
up of neutral phospholipids and myeloid body formation.
Support for this hypothesis comes from lipid analysis of membranes in
renal cells treated with aminoglycosides. Feldman and coworkers (1982) found
that the increase in PI concentration was an early effect and hence may be part
of the pathogenesis. Since aminoglycosides are known to bind with PI at the
apical membrane, they postulated that it might also be related to uptake. PI,
though, is not one of the predominant lipids in myeloid body formation in
fibroblasts (Oshima et al., 1989).

Rather, phosphatidyl choline, bis-

(monoacylglycerol) phosphate, and phosphatidylserine show the greatest
increase. Oshima’s group (1989) further suggested that actual myeloid body
formation may not be the cytotoxic mechanism, but rather, cytotoxicity may
result from aminoglycoside binding to organelles other than lysosomes.
PI is located on the inner leaflet of the cell membrane, so clearly, to
affect these molecules, aminoglycosides must somehow enter the cytoplasm of
the hair cells.

There is evidence that this occurs early during exposure to
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aminoglycosides (Wedeen et al., 1983). In fact, aminoglycoside sequestration
in the lysosome may even be an adaptive response to protect the cell from
damage (Williams et al., 1984; Wedeen et al, 1983).
Simmons and associates (1980) found that mitochondria of rat kidneys
treated with gentamicin had decreased cellular respiration, and the cells had
less ATP than controls.

The parallel with bacterial cytochrome systems is

inescapable. It would be reasonable to presume that the inhibition of Na/K
ATPase seen in renal cells might also apply to hair cells. For a hair cell which
depends on membrane potential for its function, this inhibition might also
affect cell viability. Other intracellular aminoglycoside effects would include
inhibition of protein kinase C (Hagiwara et al., 1988) and stimulation of
messenger-independent protein kinases (Ahmed et al., 1988).
It is unclear which of these observations are related to the actual
mechanism of cytotoxicity and which are epiphenomena.

It does seem,

however, that PI metabolism is a crucial factor. Further research needs to be
done to discover exactly how these compounds affect bacteria and how it
relates to hair cell death and other side-effects.

RISK FACTORS
In the various studies of the ototoxic effects of the aminoglycoside
antibiotics, several factors have been identified which seem to be correlated
with increased risk of vestibular damage [Table 2].

Renal insufficiency

(especially when aminoglycoside dosage is not adjusted accordingly), high
serum concentrations of the drug, duration of therapy, and previous treatment

19
with aminoglycosides have been noted as factors by multiple authors (Edson
& Terrell, 1987; Arcieri et al., 1970; Jackson & Arcieri, 1971; and Wilson et al.,
1984; Nordstrom et al., 1973).

Obesity, preexisting auditory impairment,

bacteremia, dehydration, and poor liver function have also been implicated
(Gilman et al., 1985).
In their work on aminoglycoside side-effects, Moore and associates
(1984) surveyed

135

patients who had received

at

least

9 doses

of

aminoglycoside antibiotics. They found total dose, duration of therapy, peak
temperature, bacteremia, liver dysfunction, and dehydration to be risk factors
for hearing loss.

To explain some of these results, they speculated that if

prostaglandin E is cytoprotective against the effects of bacterial endotoxins or
leukocyte pyrogen on the hair cells, then aminoglycosides might be indirectly
responsible by blocking PLC (Lipsky & Lietman, 1982).

PLC cleaves DG

from PI which can serve as a precursor of arachidonic acid and eventually
prostaglandin E (Zubay, 1983).

Furthermore, they postulated that the

increased risk in those with liver dysfunction might somehow be related to
CNS depression seen in liver failure. They were unable to correlate hearing
loss with hematocrit, age, bicarbonate concentration, sex, presence of urinary
tract infection or pneumonia, prognosis, or use of clindamycin, cephalothin,
or furosemide. They did not examine vestibular toxicity.
Another potential risk factor is poor nutrition. In guinea pigs that were
food-restricted (but received water ad lib), Prazma and coworkers (1983) noted
enhanced hair cell death in those subjects that received tobramycin or
gentamicin. They elicited no altered serum pharmacokinetics, and suggested
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TABLE 2
AMINOGLYCOSIDE OTOTOXICITY RISK FACTORS
RISK FACTOR

TOXICITY* MODEL**

CITATION

renal insufficiency

V
V,A
V
A
V,A

H
H
H
H
H

Nordstrom et ah, 1973
Finegold et al., 1958
Tjernstrom et al., 1973
Fee, 1980
Neu & Bendush, 1976

prior treatment

V,A
V
V

H
H
H

Edson & Terrell, 1987
Wilson et al., 1984
Tjernstrom et al., 1973

high serum concen.

V,A
V
V
V,A

H
H
H
H

Edson & Terrell, 1987
Wilson et al., 1984
Nordstrom et al., 1973
Finegold et al., 1958

treatment duration

V
A

H
H

Nordstrom et al, 1973
Moore et al., 1984

high temperature

A
A
A

H
H
A

Fee, 1980
Moore et al., 1984
Flenry et al., 1983

semistarvation

A

A

Prazma et al., 1983

noise

A
A

A
A

Brown et al., 1980
Jauhiainen et al., 1978

liver dysfunction

A

H

Moore et al., 1984

bacteremia

A

H

Moore et al., 1984

dehydration

A

H

Moore et al., 1984

total dose

A

H

Moore et al., 1984

auditory dysfunct

V

H

Tjernstrom et al., 1973

hematocrit

V

H

Fee, 1980

other drugs

V,A

H

Neu & Bendush, 1976

* vestibular toxicity = V, auditory toxicity = A
** human data = H, animal data = A
auditory dysfunct = a history of preexisting auditory dysfunction,
other drugs = concomitant use or other ototoxic drugs such as furosemide or
vancomycin.
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that the decreased glomerular filtration rate seen with semistarvation may
increase serum levels of the drug and thereby lead to ototoxicity.
Noise has been shown to potentiate the auditory toxicity of the
aminoglycosides. In the cochlea. Brown and associates (1980) using kanamycin
and Jauhiainen and colleagues (1972) using neomycin found the number of
hair cells lost by subjecting guinea pigs simultaneously to both noise and
kanamycin far outstripped the sum of the two agents when used alone. Since
Hawkins (1971) has shown that noise causes vascular changes which induce
hair cell ischemia. Brown and coworkers (1980) suggested that noise renders
the cells more vulnerable to the effects of aminoglycosides. Noise, however,
had no effect on the pharmacokinetics of kanamycin, and it has never been
shown to be a factor in vestibular toxicity.
Finally,

observing

that

preweanling

mice

exposed

to

elevated

temperatures suffered from increased aminoglycoside ototoxicity as measured
by electrocochleography, Henry and associates (1983) speculated that fever
might also be a risk factor in humans.

They postulated that increased

metabolic demands from hyperthermia could leave the hair cells more
vulnerable, and they suggested that noise and even hyperthyroidism might
work in the same fashion.

They attempted to control for dehydration with

daily weighings and injections of dilute solutions of aminoglycosides.
Nevertheless, dehydration may also have played a role. They did not examine
the vestibular apparatus.
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ELDERLY
The elderly are a unique population when it comes to pharmacotherapeutics, and many authors have speculated that they might have an
increased risk of vestibular damage (Edson & Terrell, 1987; Lampe, 1986;
Appel & Neu, 1978; Nordstrom et ah, 1973; and Tjernstrom et al, 1973).
Studies on vestibular toxicity among elderly patients, however, have not
confirmed this speculation (Fee, 1980; Lane et ah, 1977; Lerner et ah, 1977;
Neu & Bendush, 1976; Nordstrom et ah, 1973; and Finegold et ah, 1958). One
reason for the negative research findings is the low incidence rate and low
power of some of the studies. Jackson & Arcieri (1971) reviewed 70 of the 72
cases of ototoxicity that occurred during the gentamicin clinical trials from
1962-1969 and found the effect to be variable.

Overall, there was no age

difference between those with and without ototoxicity. However, patients with
renal insufficiency and toxicity were younger.

While not statistically

significant, patients with normal kidneys and ototoxicity were older.
Speculation about a possibly increased risk comes about for a variety of
reasons.

First of all, the aged have a higher incidence of adverse drug

reactions (Hurwitz, 1969). This may be due to inadequate compliance with
instructions, the presence of multiple diseases, and polypharmacy (Ljungberg
& Nilsson-Ehle, 1987). Secondly, they seem to have a heightened sensitivity
to certain drugs independent of serum concentration (Gordon & Preiksaitis,
1988; Castledon et al., 1977).

Finally, a host of changes take place in the

aging body which may alter the pharmacokinetics of therapeutic agents
(Ljungberg & Nilsson-Ehle, 1987 & Schmucker, 1984).
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Of those which have an impact on aminoglycoside distribution, fluid
shifts secondary to hemodynamic instability are frequently seen in critically ill
surgical patients, many of whom are elderly (Dasta et al., 1988). Moreover,
the elderly might theoretically have a smaller volume of distribution for watersoluble drugs, such as the aminoglycosides, due to a decrease in lean muscle
mass and an increase in fat.

For example, the percentage of body fat can

increase from 18 to 36% in men and from 33 to 48% in women (Greenblatt et
ah, 1982). This means that the same dose which produces appropriate levels
in a 40-year-old may cause an overdose in a patient over the age of 70 with the
same weight. Furthermore, the aging kidney suffers a 1-2% per year decline
in blood flow, an eventual 50% reduction in glomerular filtration rate, a loss
of functioning nephrons, a decrease in secretory/absorptive capacity, and a
high incidence of spontaneous glomerular sclerosis (Schmucker, 1984).
This decline in renal function can dramatically increase the half-life of
substances, such as the aminoglycosides, which are renally eliminated, and it
is of paramount importance (Vartia & Leikola, 1960). In fact, when controlled
for renal function, hematocrit, fever, penicillin usage, and percentage of ideal
body weight, Bauer & Blouin (1983) found that neither clearance, half-life, nor
volume of distribution of gentamicin, tobramycin, or amikacin varied with age.
Not only does this run counter to the notion that they would have a lower
volume of distribution due to loss of lean body mass, but it also suggests that
renal status and not age per se is the critical factor.
In their review of the literature, Kjungberg & Nilsson-Ehle (1987)
concluded that as a group, based on available data, the elderly had no
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substantial reduction in metabolism or absorption of pharmacological agents.
There

is,

however,

substantial

individual

variation.

The

literature,

unfortunately, is very sparse, and there may be other age-related factors which
influence the pharmacokinetics of the aminoglycosides in ways which have yet
to be elucidated.

It is certainly difficult to perform adequately controlled

studies due to the large number of variables such as multiple disease states,
polypharmacy, and variations in activity levels which must be addressed.
If the elderly do have an increased incidence, the question still remains
as to why the aminoglycosides might preferentially affect the elderly.

One

possibility is that the 20-40% decrease in the number of vestibular hair cells
associated with aging (Rosenhall, 1973) might simply leave elderly patients
with fewer cells to lose before they become symptomatic.

This is consistent

with observations that patients treated with previous doses of aminoglycosides
and patients with preexisting auditory impairment suffer from increased risk
of vestibular toxicity (Gilman et al., 1985; and Wilson et al., 1984). Like the
elderly, these patients might be expected to have fewer hair cells to lose before
becoming symptomatic.

Other researchers have speculated that chronic

diseases and poor appetite may reduce some elderly patients to a state of
semistarvation which they found to be one of the risk factors (Prazma et al.,
1983).

Renal

disease

might

also

contribute.

Creatinine

clearance

measurements are flawed because tubular secretion of creatinine causes
overestimation of glomerular filtration rate (GFR), and this effect worsens in
cases of declining GFR such as are seen in the aged (Kim et al., 1969). This
may cause clinicians to overestimate renal function and administer more toxic
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doses. Moreover, the replacement of lean body mass with adipose tissue seen
in aging leads to a decrease in creatinine production which further complicates
calculations (Greenblatt et al., 1982). Finally, as Fowler (1947) pointed out,
elderly patients are less able to compensate for aminoglycoside-induced
vestibular damage and might present themselves earlier.

In that sense, the

elderly, with their impaired ability to compensate for vestibular damage, are
a unique population ideally suited for studying vestibular toxicity.

FUTURE USAGE
The question of whether the elderly are at increased risk is a significant
one, and it is intimately related to the debate over the aminoglycosides’ place
in current clinical practice. The three important considerations are side-effects,
economics, and efficacy.

The side effects have already been discussed, and

their economic implications are magnified when examined in the setting of an
elderly population.
Those over the age of 65 currently make up 12% of the 251 million
people in this country. By 2030 their ranks will swell to 21% of 317 million
people (Waldo et al., 1989). Since they disproportionately consumed 36% of
the $447 billion health care dollars spent last year, their physical health has a
major impact on the economic health of the country both now and in the
future.

The monetary and human costs of an increase in dizziness among

elderly patients therefore becomes significant.

Dizziness and balance

abnormalities are important risk factors in predicting the likelihood of falling
(Tinetti et al., 1988; Tinetti et al., 1986). Roughly 30% of community-living
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persons over the age of 65 are estimated to fall each year, and many of these
falls are dizziness-related (Prudham & Evans, 1981).

The decreased bone

density seen with osteoporosis can transform a relatively minor fall into the
tragedy of a hip fracture which carries a 15-30% one-year mortality rate in
patients over the age of 60 (Kenzora, 1984). The economic cost is staggering,
with the 1980 total annual cost of new hip fractures estimated at $2 billion
(unpublished paper quoted in Baker & Harvey, 1985).
There are other costs involved as well. Compared to some of the newer
agents designed to replace them, the acquisition cost of aminoglycosides
appears cheap at first glance.

Since aminoglycosides are often used in

combination with other agents, the added acquisition cost of using other agents
must be added as well. Moreover, Eisenberg (1987) found that the cost of an
individual patient with an episode of nephrotoxicity is $2,501 to the hospital
and $5,376 to the third party payer.
hospital

per course of therapy,

Therefore, the additional cost to the

distributed

among all

patients using

aminoglycosides, is $183 per patient. Furthermore, there is an additional cost
of routinely monitoring drug serum levels, BUN, and serum creatinine that
would not be incurred if safer antibiotics were used. This cost can range from
$75-200 per patient (Sochalski et ah, 1988). Finally, when compared to single
agent therapy, there is also the further expense incurred by increasing the
workload of nurses, pharmacists, and other staff as well as the need for more
equipment such as needles, bottles, etc. (Quintiliani et ah, 1986).
The third consideration in deciding the place of aminoglycosides is
therapeutic effectiveness.

Efforts to modify aminoglycoside molecules to
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reduce the toxicity without decreasing efficacy have failed and have largely
been abandoned (Pancoast, 1988). Nevertheless, new classes of antibiotics and
regimens of combination therapy have arisen and have shown some promise.
For many CNS infections, third generation cephalosporins are now preferable
when aerobic gram-negative organisms are involved (Pancoast, 1988). Betalactams are also replacing aminoglycosides for abdominal and pelvic mixed
infections because of their superior gram-positive and anaerobic coverage
(Pancoast, 1988; Quintiliani et al., 1986). For example, a study here at Yale
has demonstrated that there is no major difference between cefotetan and
combination therapy which includes aminoglycosides in the treatment of a
variety of anaerobic infections (Sochalski et ah, 1988).
In their review of the literature, DiPiro & Bowden (1989) concluded that
aztreonam was at least as effective as aminoglycosides for lower respiratory,
intra-abdominal, and other infections with gram-negative organisms including

P. aeruginosa. Ceftazidime and cefoperazone have excellent activity against
P. aeruginosa and are being used as single agent therapy in a variety of
situations (Quintiliani et ah, 1986).

Imipenem-cilistatin is another excellent

alternative to the aminoglycosides (DiPiro & Bowden, 1989).

In

summary,

the

aminoglycoside

antibiotics

can

reach

high

concentrations with a protracted half-life in the endolymph where they are
toxic to vestibular hair cells. The exact mechanism is unknown, but elderly
patients may have an increased risk.

This study examined this special

population and attempted to determine if, indeed, the elderly are at increased
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risk of vestibular damage.

When the aminoglycosides were first introduced,

it was felt that although they had significant side-effects, their use was justified
because of their impressive clinical effect in certain infections.

With the

introduction of new, safer antibiotics into our clinical armamentarium, it may
once again be time to reevaluate their place in current medical practice.
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METHODS
A prospective observational cohort design was chosen for this study.
This design is the least intrusive to both subjects and hospital staff while still
allowing for effective collection of data.

SUBJECTS AND SETTING
The potential subjects in this study were all in-patients at the Yale-New
Haven Hospital (New Haven, CT), the West Haven Veterans Administration
Hospital (West Haven, CT), or St. Mary’s Hospital (Waterbury, CT) who were
discharged between August and December of 1990.

These facilities are,

respectively, a university hospital, a veterans hospital, and a community
hospital. Both male and female community-living and nursing home residents
over the age of 65 were included.
The study (exposed) group comprised those who were treated with an
intravenous antibiotic course which included at least five days of any
aminoglycoside. The control (unexposed) group had at least a five day course
of antibiotics in which one of the control drugs was used.

Since

aminoglycosides are used predominantly for Pseudomonas coverage, betalactam antibiotics such as aztreonam, imipenem, ceftazidime, or one of the
ant [-Pseudomonas penicillin (azlocillin, mezlocillin, carbenicillin, ticarcillin, or
piperacillin) were selected as the control drugs due to their similar spectrum.
Subjects who received more than one course of IV antibiotics during their
hospitalization were included, but if they received aminoglycosides, they were
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placed in the "exposed" group. Antibiotics administered topically, as eyedrops,
or via bladder irrigation were ignored since their systemic effects would be
minimal.
An effort was made to include a broad a spectrum of subjects to make
the results as generalizable as possible.

Subjects were excluded, however, if

they had preexisting severe renal disease (serum creatinine >3.5) or were
hospitalized more than four months because it would have greatly complicated
interpretation of results. Additionally, those subjects who were rehospitalized
between the time of the index hospitalization and the time of the telephone
interview were excluded.

For practical purposes, subjects who were deaf,

mute, or cognitively impaired (unable to provide accurate answers to survey
questions), could not be contacted by telephone, or were in hospice at the time
of the telephone interview were likewise excluded from the study.
The names of potential subjects were obtained from lists provided by the
hospital pharmacies or medical information services [Table 3]. The printouts
from each hospital differed as to the screening criteria. The pharmacy printout
from St.Mary’s listed 174 names of those who were at least 65 years old and
who had at least one order for one of the study antibiotics. Examination of
the pharmacy computer eliminated 114 persons due to an insufficient length
of antibiotic use. The charts for the remaining 60 patients were then requested
and examined.
The Yale-New Haven Hospital printout provided 307 names of persons
at least 65 years old along with a list of their antibiotic start and stop dates.
Charts for the 178 persons who had a sufficient course of antibiotics were
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TABLE 3
SOURCE OF STUDY POPULATION

HOSPITAL

PHARMACY
LIST

CHARTS

CHARTS
REQUESTED RECEIVED

SUBJECTS
USED

St. Mary’s

174

60

60

5

YNHH
WHVAH

307
*

178
107

108

20

79

17

345

247

42

Total
Uncountable.

Pharmacy list = list of potential subjects generated by pharmacy computer.
Charts requested = subjects from printout who meet the criteria for age and
antibiotic length as determined by the pharmacy computer.
Charts received = the number of charts requested which were received from
medical records.
Subjects used = the number of subjects meeting the study criteria who were
included in the data analysis.
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requested. Unfortunately, the hospital policy does not allow incomplete charts
to be used for research purposes.

Seventy charts remained incomplete eight

weeks after discharge and could therefore not be used in the study.
The Veterans Hospital printout was essentially a list of orders placed to
the pharmacy for stock items. The total number of subjects was uncountable
since it listed all age groups, included multiple listings for each patient, was not
alphabetized, and included requests for sterile saline, multivitamins, and other
items which were not part of the study.

Using the pharmacy computer,

however, it was possible to pare the number of potential subjects who were 65
or older and had received a sufficient course of antibiotics down to 79.
Unfortunately, it was not possible to determine from the computer if all these
subjects had been discharged or were still in the hospital. By the end of the
pilot study 28 charts from the WHVAH were not available because the
subjects were still in the hospital.
There was only one refusal (an unexposed patient from YNHH) to
participate in the study.

Medical record data from this person were not

included in the data analysis.

Of those included in the study, five subjects

came St. Mary’s, twenty came from YNHH, and seventeen came from the
WHVAH.

DATA
Once the charts were received, all demographic data, past medical
history, hospital course, medications, infecting organisms, surgical procedures,
allergies, lab data, vital signs, length of hospitalization and antibiotic usage
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were extracted from the medical record. Those subjects who met the inclusion
criteria were contacted by telephone.
Since the onset of vestibular toxicity can sometimes occur several weeks
after discontinuation of the antibiotic (Neu & Bendush, 1976), the subjects
were contacted by telephone two to eight weeks after their discharge to avoid
missing any cases. This waiting period also allowed subjects to equilibrate in
their home environment subsequent to their hospitalization.

It was felt that

increasing the time of contact beyond eight weeks after discharge could result
in an increase in recall bias by the subjects.

After informed consent was

obtained, the subjects were asked if they had dizziness, what type they had,
how severe it was, if they had a diagnosis for it, what medications they take
for it, when it began, what brings it on, when was the most recent episode, and
if they have had dizziness-related accidents.

An effort was made to identify

those cases in which dizziness could be attributed to known causes. Subjects
were also asked about vision, hearing, and alcohol use.
Although the author performed both the chart extraction and the
telephone interview, these were done in batches to decrease the likelihood that
knowledge of the antibiotic regimen would influence the interviewer. Hospital
treatment was not discussed on the telephone.

DEFINITION OF VARIABLES
Renal insufficiency was estimated using BUN (nl=8-18 mg/dl) and
creatinine (n]=0.5-1.2 mg/dl). Nutritional status was estimated using albumin
(nl=3.5-5.0). Data on liver dysfunction were taken from the admission history
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and physical and the discharge summary and based on the presence of cirrhosis
or ascites. The most abnormal lab values from each subject throughout the
admission were compiled to calculate a score on the standard APACHE II
(Acute Physiology and Chronic Health Evaluation) Severity of Disease
Classification System. Although Knaus et al. (1985) developed this scale as a
predictor of hospital mortality in ICU patients, they suggested that it could
also be used in research protocols to compare severity of disease between the
exposed and unexposed groups.
For the purpose of this study, dizziness was defined as a complaint of
lightheadedness, disequilibrium, vertigo, or other ill-defined sensations of
motion.

"New-onset dizziness" was defined as dizziness that could not be

ascribed to any other known process and which had begun since the
hospitalization. "Increased severity" or "increased frequency" of dizziness since
the hospitalization were based on the subjects’ subjective opinions. Those with
new-onset dizziness were automatically considered to have both an increased
severity and frequency of dizziness.

A subject was considered to have

"worsened dizziness" if he or she complained of either new-onset dizziness, an
increase in the severity of dizziness, or an increase in the frequency of dizziness
episodes.
Assessment of post-hospitalization activity levels was based on a
modified life-space diameter in which subjects were segregated according to
their ability to get out of bed, leave the home, and leave the home without
assistance (May et al, 1985).

Those who left their home were asked to

quantitate the number of blocks they felt they could walk on a given day.
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Finally, obesity was estimated using self-reported height and weight to
compute a body mass index (BMI), which is the weight in kilograms divided
by the square of the height in meters (Stavig et al., 1984).

STATISTICAL ANALYSIS
Data were stored on an Optima 386SX personal computer, and
statistical analyses were carried out using a standard statistical package (SAS
Institute Inc. Cary, NC, 1987). Chi square analyses were used to analyze
dichotomous data which had at least five items in each cell. The remainder of
the dichotomous data were analyzed using the Fisher exact test. Student’s Ttests were used to analyze dimensional data [Table 4],
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TABLE 4
DATA SOURCES AND STATISTICS

DATA

SOURCE

STATISTICS

gender

chart

chi square

race

chart

Fisher exact

diuretic usage

chart

chi square

maximum BUN

chart

Student’s T-test

maximum creatinine

chart

Student's T-test

last hematocrit

chart

Student’s T-test

last systolic blood pressure

chart

Student’s T-test

last diastolic blood pressure

chart

Student’s T-test

maximum temperature

chart

Student’s T-test

APACHE II score

chart

Student’s T-test

length of hospitalization

chart

Student’s T-test

had surgery

chart

chi square

EtOH use #1

chart

Fisher exact

EtOH use #2

interview

Fisher exact

dizziness present

interview

Fisher exact

new-onset dizziness

interview

Fisher exact

increased frequency of dizziness

interview

Fisher exact

increased severity of dizziness

interview

Fisher exact

worsened dizziness
bedridden

interview

Fisher exact

interview

Fisher exact

housebound

interview

Fisher exact

leaves house alone

interview

chi square

blocks walked

interview

Student's T-test

body mass index (BMI)

interview

Student’s T-test

hearing

interview

Fisher exact

Worsened dizziness = report of new-onset dizziness or an increase in
frequency or severity of dizziness.
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RESULTS
The average age (+/-SD) of the 42 subjects was 73.5 (+/- 6.23). Twenty
four (57%) were male and 18 were female (43%).

Thirty-five (83%) lwere

white, three (7%) were black, and 4 (10%) did not have their race listed in the
chart.
There were 26 (62%) unexposed and 16 (38%) exposed subjects.
Although the study was open to all persons with five or more days of
treatment with any aminoglycoside, in actual fact the exposed group is only
made up of subjects who received gentamicin. This probably reflects the local
pattern of antibiotic prescription. Among the unexposed subjects, 15 received
cefoperazone, 4 received ceftazidime, 3 received ticarcillin, and 4 received
mezlocillin as their primary antibiotic [Table 5]. Again, all the control drugs
were not represented.
Of the 42 subjects, 10 (63%) of the exposed and 14 (54%) of the
unexposed subjects were males, and there was no statistically significant
difference in gender distribution between the populations by chi square (p =
0.58). Fourteen (88%) exposed and 21 (81%) unexposed subjects were white.
Two (12%) exposed and one (4%) unexposed subject were black. There was
no statistically significant racial difference between the exposed and unexposed
subjects by Fisher exact test (white: p = 0.69, black: p = 0.55). Four of the
unexposed subjects did not have their race listed in the chart.

The

distribution of subjects having surgery during the admission in question was
also not statistically significant by chi square (p = 0.74)[Table 6].
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TABLE 5
PRIMARY ANTIBIOTIC USED

ANTIBIOTIC

# OF SUBJECTS (%)

gentamicin

16 (38%)

cefoperazone

15 (36%)

ceftazidime

4 (9.5%)

mezlocillin

4 (9.5%)

ticarcillin

3 (7.0%)

The populations were compared using a student’s T test for age,
maximum BUN, maximum creatinine, minimum albumin, last hematocrit,
maximum temperature, last blood pressure, length of hospitalization, and body
mass index.

The Student’s T test was also used to compare self-reported

activity levels (in blocks walked per day) and APACHE II scores.

None of

these variables were found to be statistically significant except length of
hospitalization [Table 7]. Unexposed subjects remained in the hospital for 25
(+/-17) days compared to exposed subjects who were hospitalized only 15 (+/12) days (p = 0.036).
When the exposed and unexposed subjects were compared by Fisher
exact test for activity levels, there was no statistically significant difference in
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TABLE 6
COMPARISON OF EXPOSED AND UNEXPOSED SUBJECTS
NOMINAL DATA
VARIABLE
gender
male
female
race
white
black
unlisted
surgery
yes
no
bedridden
yes
no
housebound
yes
no
refused to answer
can leave home alone
yes
no
refused to answer
alcohol use #1
more than social
none or social
unlisted
alcohol use #2
more than social
none or social
refused
hearing
good
poor
diuretics
used
not used

EXPOSED
(n=16)

UNEXPOSED
(n=26)

10 (63%)
6 (37%)

14 (54%)
12 (46%)

0.58 §

14 (88%)
2 (12%)
0 (0%)

21 (81%)
1 (4%)
4 (15%)

0.69 If
0.55 1

9 (56%)
7 (44%)

16 (62%)
10 (38%)

0.74 §

0 (0%)
16 (100%)

1 (4%)
25 (96%)

i.oi

1 (6%)
15 (94%)
0 (0%)

4 (16%)
21 (80%)
1 (4%)

0.63 1

9 (56%)
7 (44%)
0 (0%)

16 (64%)
9 (32%)
1 (4%)

0.62 §

3 (38%)
13 (62%)
8 (50%)

3 (15%)
17 (62%)
6 (23%)

0.31 1

5 (31%)
11 (69%)
0 (0%)

3 (12%)
22 (84%)
1 (4%)

0.23

13 (81%)
3 (19%)

23 (88%)
3 (12%)

0.66 If

6 (38%)
10 (62%)

17 (68%)
9 (32%)

0.044 §

P=

* = Alcohol use greater than "social" use or at least once per day. Variable #1 is
obtained from the chart and #2 is obtained during the survey.
** = Subject can hear a friend talking in room.
= Fisher exact test
§ = chi square
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Table 7
COMPARISON OF EXPOSED AND UNEXPOSED SUBJECTS
DIMENSIONAL DATA
VARIABLE

TEST

EXPOSED

UNEXPOSED

Age

range
mean (+/- SD)

65-88
75.7 (6.7)

66-86
72.1 (6.1)

0.086

range
mean (+/- SD)

10-91
31.4 (19.8)

13-80
29.8 (17.8)

0.79

range
mean (+/- SD)

1.0-3.4
1.79 (0.68)

0.7-2.8
1.48 (0.54)

0.12

range
mean (+/- SD)

2.1-4.2
2.92 (0.67)

1.0-4.9
2.84 (0.92)

0.81

range
mean (+/- SD)

30-43
34.9 (3.6)

26-45
35.0 (5.2)

0.95

range
mean (+/- SD)

98.8-106.6
101.8 (2.1)

98.8-103.8
101.3 (1.4)

0.29

range
mean (+/- SD)

100-160
127.5 (16)

110-175
130.9 (18)

0.54

range
mean (+/- SD)

60-90
71.9 (10)

56-100
71.6 (11)

0.93

Length of
Hospital Stay

range
mean (+/- SD)

6-53
15.0 (12)

6-68
25.4 (17)

0.036

Body Mass
Index

range
mean (+/- SD)

16.9-31.4
25.3 (4.5)

16.2-40.0
25.1 (6.5)

0.94

APACHE II

range
mean (+/- SD)

5-43
15.9 (9.9)

6-39
17.5 (8.5)

0.59

range
mean (+/- SD)

0-12
2.9 (3.1)

0-6
1.5(1.5)

0.051

BUN
Creatinine
Albumin
Hematocrit
Temperature
Systolic BP
Diastolic BP

Activity
level

P=

Activity level is the reported number of blocks the subject can walk per day.
p values calculated using a Student’s T-test.
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the distributions of those who were bed-ridden or house-bound (p values 1.0 and 0.63
respectively). When asked if they could leave their home without assistance, 9 (56%)
exposed and 16 (64%) unexposed answered in the affirmative.

There was no

statistically significant difference between the populations by chi square test for this
variable (p = 0.62).
As a crude measure of visual acuity, subjects were asked if they could see well
enough to recognize a friend across the room.

All subjects answered in the

affirmative. To assess hearing, subjects were asked if they could hear a friend talking
to them from across the room. Thirteen (81%) exposed and 23 (88%) unexposed
subjects felt they could do so.

There was no significant difference between the

populations by Fisher exact test (p = 0.66). When liver function was examined, it
was noted that one unexposed subject had hepatitis of unknown etiology and one had
cirrhosis (2/26, 7.7%). Only one (6.2%) exposed subject had liver pathology. In this
case it was alcoholic hepatitis. The small number of subjects with liver disease makes
it difficult to do statistical analysis, but the incidences appear similar.
Although not statistically significant by Fisher exact test, alcohol use seemed
to be higher in the exposed population than the unexposed population. This was true
both for data obtained from the chart (p = 0.31) and data obtained over the (p =
0.23). There was a 78% agreement between the chart information and the telephone
survey for this variable.

A kappa of 0.27 showed that there was poor agreement

between the two reports of alcohol use. The difference between the populations for
diuretic usage was statistically significant by chi square. Only 6 (38%) of exposed
subjects received diuretics while 18 (69%) of unexposed subjects received them (p =
0.044).
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ASSESSMENT OF DIZZINESS
Subjective reports of dizziness were assessed in the telephone interview. Five
(31%) subjects reported experiencing episodes of feeling dizzy, lightheaded, or faint.
Seven (27%) unexposed subjects in the exposed group reported these symptoms (p=
1.0)[Table 8],

For the question "Did you have this [dizziness] prior to your

hospitalization?" 12.5% (2) of the exposed subjects as compared to 7.7% (2) of the
unexposed subjects answered affirmatively (p = 0.63). When questioned as to an
increase in the frequency of dizziness episodes since their hospitalization, two exposed
(13%) and three (11.5%) unexposed subjects felt there was an increase (p = 1.0). A
full 18.8% (3) of the exposed subjects reported an increase in the severity of dizziness
compared to only 8.0% (2) of the unexposed subjects, but again this was not
statistically significant by Fisher exact test (p = 0.36).

Finally, when subjects

reporting new-onset dizziness or an increase in severity or frequency of episodes were
grouped together under the category of worsened dizziness, 18.8% of the exposed (3)
and 11.5% (3) of the unexposed subjects had worsened dizziness since their
hospitalization (Fisher exact p = 0.66). Based on these percentages, the relative risk
of worsened dizziness for elderly patients after receiving at least five days of
aminoglycoside therapy is 1.09 (95% confidence interval: 0.152-16.98).
Of those who reported dizziness, two unexposed subjects and no exposed
subjects suffered a fall between their discharge and the telephone call. One subject
fell five times and reported dizziness prior to some of the falls. The other subject fell
once and was not dizzy at the time.
There were differences in the exposed and unexposed populations for four
variables (age, length of hospitalization, diuretic use, and the number of blocks the
subjects could walk) which were either statistically significant or close to it. Each
variable was made binary. Age was divided into an older cohort (over 74 years old)
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and a younger cohort (74 and under). Length of hospitalization was stratified into
those hospitalized for 20 days or more and those hospitalized for less. The number
of blocks walked was divided into two or less and three or more. Diuretic usage was
already a binary variable.

Table 9 presents the number of subjects and the

percentages in each group. The sample size was not large enough to perform the
Mantel-Haenszel chi square or relative risk.
Diuretic usage was seen in 1 (17%) exposed and 2 (11%) unexposed subjects
who reported worsened dizziness.

Three (33%) of the exposed and only 1 (13%)

unexposed subjects were 74 years old or older. A hospitalization of 20 or more days
was seen in 2 (67%) of the exposed and 2 (15%) of the unexposed subjects who
reported worsened dizziness.

Finally, worsened dizziness was reported in 2 (25%)

exposed and 1 (25%) unexposed subjects who walked 3 or more blocks.
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TABLE 8
COMPARISON OF EXPOSED AND UNEXPOSED SUBJECTS
DIZZINESS OUTCOME

EXPOSED
n = 16

UNEXPOSED
n = 26

P=

dizziness (new or old)
present
absent

5 (31%)
11 (69%)

7 (27%)
19 (73%)

1.0

new-onset dizziness
present
absent

2 (13%)
14 (87%)

2 (8%)
24 (92%)

0.63

dizziness frequency
increased
decreased or unchanged
refused to answer

2 (13%)
13 (81%)
1 (6%)

3 (12%)
23 (88%)
0 (0%)

1.0

dizziness severity
increased
decreased or unchanged
refused to answer

3 (19%)
13 (81%)
0 (0%)

2 (8%)
23 (88%)
1 (4%)

0.36

worsened dizziness
present
absent

3 (19%)
13 (81%)

3 (12%)
23 (88%)

0.66

VARIABLE

p values calculated using Fisher exact test.
New-onset dizziness -

reports of dizziness which was not present prior to

hospitalization.
Worsened dizziness = reports of either new-onset dizziness or an increase in frequency
or severity of dizziness.
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TABLE 9
STRATIFICATION OF WORSENED DIZZINESS*
BY POTENTIAL CONFOUNDING VARIABLES

VARIABLE

SUBJECTS REPORTING WORSENED DIZZINESS
EXPOSED (%)

UNEXPOSED (%)

n = 16

n = 26

yes (n=24)

1/6 (17%)

2/18 (11%)

no(n=18)

2/10 (20%)

1/8 (13%)

yes (n=l 7)

3/9 (33%)

1/8 (13%)

no (n=25)

0/7 (0%)

2/18 (11%)

20 or more days (n = 17)

2/3 (67%)

2/13 (15%)

less than 20 days (n=25)

1/13 (8%)

1/13 (8%)

3 or more (n=12)

2/8 (25%)

1/4 (25%)

less than 3 (n=30)

1/8 (13%)

2/22 (9%)

Diuretic use

Age over 73 years old

Hospitalization

Blocks walked

Worsened dizziness^ reports of either new-onset dizziness or an increase in the
frequency or severity of dizziness episodes.

46

DISCUSSION
Elderly subjects who received in-hospital aminoglycosides and elderly
subjects who did not receive these agents were compared for subjective
reporting of dizziness.

This pilot study demonstrated a trend in which the

aminoglycoside-exposed population subjectively reported a higher rate of newonset dizziness, worsened dizziness, or increased severity of dizziness than those
who had not received them.

This trend shows a 5-11% higher incidence of

symptoms in those who received aminoglycosides, and it is larger than the 22.5% range of historical controls for gentamicin toxicity (Jackson & Arcieri,
1971; Arcieri et al., 1970).

This suggests that elderly patients may have an

increased risk of aminoglycoside-induced dizziness.
It is possible that this population differs from the populations studied
in the other protocols in some significant way other than age. Moreover, the
trend was not statistically significant, so the small sample size did not permit
a more definitive conclusion. If the elderly do not actually have an increased
risk of dizziness, there are many reasons why a trend could have artifactually
been found.

First, the choice of antibiotic, and hence the separation into

exposed and unexposed groups, was not randomized or even controlled by the
investigators.

This could lead to a susceptibility bias (Horwitz et al., 1985)

since the reasons for administering (or not administering) aminoglycosides
could somehow be related to a predisposition to vestibular toxicity.
example,

For

since clinicians who felt that subjects had a high risk for

aminoglycoside-induced side-effects would be less likely to use these agents,
one would expect to find less dizziness in the exposed group.
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Secondly, the observed trend could also result from unmeasured
differences between the exposed and unexposed populations. No statistically
significant differences, however, were found between the populations for
variables such as age, gender, race, various lab values, occurrence of surgery
during the admission, hearing, vision, or level of activity. Commonly cited risk
factors for aminoglycoside vestibular toxicity such as renal insufficiency,
obesity, liver dysfunction, starvation, and peak temperature were surveyed, and
no statistically significant difference between the populations were noted.
Severity of illness was assessed using APACHE II scores, and although
unexposed subjects were hospitalized longer, there was no statistically
significant difference between the two populations.

Maximum BUN and

creatinine were used as a crude measure of hydration status.

The hospital

charts did not contain sufficient information to examine preexisting auditory
impairment or the effects of noise on these patients.

Moreover, since all

patients did not have blood culture results, it was not possible to accurately
assess bacteremia.

Finally, since serum levels of the beta-lactams are not

routinely measured, it was not possible to compare the populations for possible
overdosage of antibiotics.
Nevertheless, there were some significant differences between the two
study populations.

When the dizziness outcomes were stratified by these

variables, exposed subjects still had a higher percentage of reports of worsened
dizziness than unexposed subjects in both diuretic groups, the older age group,
the longer hospitalization group, and the less active group.

Exposed and

unexposed subjects were equal in their reporting of worsened dizziness in the
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most active group and the short hospitalization group, but a higher percentage
of the exposed population came from these two groups. By having a higher
percentage of the exposed subjects in subpopulations where there was no
difference between exposed and unexposed subjects in terms of worsened
dizziness, the overall magnitude of the difference between the exposed and
unexposed subjects would therefore be lower.

There were more reports of

dizziness among unexposed subjects in the younger age group than among the
exposed subjects.

Since 69% of the unexposed subjects were younger while

only 44% of the exposed subjects were younger, this would increase the
incidence of dizziness seen in the unexposed group. Thus the net effect of the
latter three confounding variables seems to be to decrease the observed trend.
Although proper statistics were not done because of the sample size, taken
together the results indicate that older subjects who were less active and had
longer hospitalizations had a higher incidence of dizziness when given
aminoglycoside antibiotics.
The sample size was the greatest limitation of the study.

Given the

breadth of the information collected in this study, it would have been very
interesting to use a variety of other statistical tests, such as multivariant
analysis, on the data.

This was not possible due to the small sample size.

Additional subjects would also be needed to compare the populations for
occurrence of specific types of concurrent medical

problems,

surgical

procedures, and medications. Another limitation of the study was that only
a small percentage of the potential population was utilized. Although efforts
were made to include a broad a spectrum of subjects, a large number of
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subjects were unavoidably excluded due to restrictions on the review of medical
charts.
Based on the current sample size, the power of this study to demonstrate
at the 5% level a difference the magnitude of the observed trend is very small.
Assuming the frequencies noted in this study are the actual frequencies which
would be seen if the entire population over the age of 65 was sampled, the
sample size needed to increase the power to 85% at an alpha of 5% would be
roughly 250 subjects in each arm for a total of 500 subjects.

Using the

maximum rate of data collection, it would require approximately three years
to complete the study.
If this pilot study had detected an actual difference secondary to
aminoglycoside use, it could be due to the myriad of pharmacokinetic changes
inherent in aging. Bauer & Blouin’s (1983) work, though, suggests that these
changes do not apply to aminoglycosides. More likely, aminoglycoside usage
takes its toll on the vestibular hair cell population in all patients regardless of
age even if given subtherapeutically in a manner similar to the effect on rat
kidneys seen by Houghton et al. (1988). Therefore, the age-associated decline
in the number of vestibular hair cells observed by Rosenhall (1973) and an
inability to adequately compensate for their loss simply leaves elderly patients
with fewer hair cells to lose before they become symptomatic.
Clearly, more work needs to be done in this area. Since many of the
other studies used the relatively insensitive thermal test as a determination of
whether toxicity existed, it is possible that they missed the more subtle
differences, such as the increase in severity of dizziness, which were seen with
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the telephone survey.

The advantage of the thermal test is that it provides

more objective data than the telephone survey. Future studies might benefit
from integrating both approaches into the protocol. Although only gentamicin
was actually used, this study also attempted to examine all the aminoglycosides
as a group. By specifically focusing on gentamicin, which has a higher rate of
vestibular toxicity, future studies would require fewer subjects to demonstrate
a difference between the study groups.
Despite the length of time required, the trend indicates it is useful to
pursue this line of research. An increase in dizziness symptoms in a geriatric
population would be clinically significant. Dizziness can lead to falls and to
the tragedy of a hip fracture. Although only two subjects fell during the brief
tenure of this study, one would expect that the number of falls would increase
as the subjects recuperated from their hospitalizations and became more active.
Those with dizziness or balance abnormalities might also be expected to fall
more frequently. Continuation of the study might settle the debate over the
possibility of increased risk among geriatric patients, and through more careful
antibiotic use, might decrease the incidence of life-threatening hip fractures and
other injuries.

SUMMARY
The significant toxicities of the aminoglycosides are well-recognized, and
vestibular toxicity is already known to be one of them. This study focused on
the question of whether the elderly are at an increased risk of aminoglycosideinduced vestibular damage.

Subjects who were exposed to aminoglycosides
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and those who were unexposed were compared for subjective reporting of
dizziness.

Those subjects exposed to aminoglycosides reported a higher

incidence of dizziness symptoms than both the unexposed subjects and the
historical controls.

Although the results were not statistically significant, it

suggests that the elderly may have an increased risk of dizziness with
aminoglycoside use.
The failure of this study to conclusively demonstrate a higher incidence
may in part be due to the study's low power.

Continuation of this study,

therefore, may offer a more complete understanding of this economically
important problem. Given the aminoglycosides’ incredible clinical success, it
may not yet be possible to substitute them for other antibiotics. Nevertheless,
their known toxicities should imbue clinicians with a healthy sense of caution
when prescribing them and a strong desire to someday find a replacement.
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